Metal free percutaneous coronary interventions in all-comers: First experience with a novel sirolimus-coated balloon.
Mehdi Madanchi, Giacomo M Cioffi, Adrian Attinger-Toller...
https://pubmed.ncbi.nlm.nih.gov/36385601/Actively Recruiting
Led by Fundación EPIC · Updated on 2026-10-29
960
Participants Needed
16
Research Sites
N/A
Total Duration
This research aims to observe and evaluate the use of the SELUTION SLRTM sirolimus-coated balloon device in treating patients with coronary artery disease, including native vessel lesions and in-stent restenosis. It is a post-market, prospective, multicenter, international, observational study without a control group, focusing on real-world patients to assess the devices safety and effectiveness in everyday clinical practice. Participants receive treatment with the SELUTION SLRTM device as decided by their treating physician. The study monitors patients who have undergone this procedure in various clinical settings, including native coronary artery stenosis and coronary restenosis. This study does not include a comparator group and follows patients longitudinally after treatment. During participation, patients are followed up for at least 12 months to assess major adverse cardiovascular events, such as death, non-fatal heart attacks, and the need for further procedures on the treated lesions. Researchers evaluate both device-oriented and patient-oriented composite endpoints. The study collects data on treatment success shortly after the procedure and monitors safety and effectiveness outcomes over the year following treatment.
CONDITIONS
Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry
O
ORIOL RODRIGUEZ LEOR, MD, PhD
F
FUNDACION EPIC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundación EPIC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant
Participants receive treatment with the SELUTION SLRTM sirolimus-coated balloon device as decided by their doctor.
Duration - 12 months
Participants are monitored for 12 months to assess major adverse cardiovascular events and treatment outcomes.
Regular follow-up visits during the year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Mehdi Madanchi, Giacomo M Cioffi, Adrian Attinger-Toller...
https://pubmed.ncbi.nlm.nih.gov/36385601/Ricardo A Costa, Sankar C Mandal, Prakash K Hazra...
https://pubmed.ncbi.nlm.nih.gov/36192319/Harald Rittger, Johannes Brachmann, Anil-M Sinha...
https://pubmed.ncbi.nlm.nih.gov/22386286/Raban V Jeger, Ahmed Farah, Marc-Alexander Ohlow...
https://pubmed.ncbi.nlm.nih.gov/30170854/Christian Spaulding, Florian Krackhardt, Kris Bogaerts...
https://pubmed.ncbi.nlm.nih.gov/36642225/Fundación EPIC
Lead Sponsor